AlzeCure Pharma AB (OSTO:ALZCUR) Payments of Debt: kr0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ALZCUR AlzeCure Pharma AB OSTO:ALZCUR
26 GF Score
Price kr7.62
! 2 Warning Signs
View Full Analysis

What is AlzeCure Pharma AB Payments of Debt?

AlzeCure Pharma AB OSTO:ALZCUR -0.78% 26 Payments of Debt is kr0.00 Mil as of Jun. 2026. GuruFocus rates OSTO:ALZCUR with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

AlzeCure Pharma AB's Payments of Debt for the three months ended in Jun. 2026 was kr0.00 Mil.

AlzeCure Pharma AB's Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was kr0.00 Mil.

AlzeCure Pharma AB Payments of Debt Related Terms

AlzeCure Pharma AB Payments of Debt Historical Data

* Premium members only.

The historical data trend for AlzeCure Pharma AB's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AlzeCure Pharma AB Payments of Debt Chart

AlzeCure Pharma AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

AlzeCure Pharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:ALZCUR
26GF Score
AlzeCure Pharma AB OSTO:ALZCUR
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AlzeCure Pharma AB Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of kr0.00 Mil mean?
AlzeCure Pharma AB (OSTO:ALZCUR) has a Payments of Debt of kr0.00 Mil as of Jun. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on AlzeCure Pharma AB and its competitors.
Is AlzeCure Pharma AB's Payments of Debt too high?
AlzeCure Pharma AB's current Payments of Debt is kr0.00 Mil. Overall, AlzeCure Pharma AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does AlzeCure Pharma AB's Payments of Debt compare to VRTX and REGN?
AlzeCure Pharma AB's Payments of Debt of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on AlzeCure Pharma AB and its competitors. AlzeCure Pharma AB's current Payments of Debt is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AlzeCure Pharma AB stock overvalued right now?
AlzeCure Pharma AB (OSTO:ALZCUR) has a current Payments of Debt of kr0.00 Mil. The current Payments of Debt is kr0.00 Mil. AlzeCure Pharma AB's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For AlzeCure Pharma AB (OSTO:ALZCUR), the current Payments of Debt is kr0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AlzeCure Pharma AB Business Description

Other Exchanges AC6:Germany
Address Halsovagen 7, Huddinge, SWE, SE 141 57
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms, NeuroRestore, Alzstatin, and Painless. The company's drug candidates include: ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.
26GF Score

Get the complete analysis for OSTO:ALZCUR

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr7.62
Price